ONCYOncolytics BiotechRunning, no new patients
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Anal Cancer Metastatic · Squamous Cell Carcinoma of the Anus Stage Unspecified · Pancreatic Cancer Metastatic · Unresectable Pancreatic Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 122 (planned)
- Started
- Oct 27, 2021
- Main results expected
- Jul 30, 2027
- Fully finished
- Dec 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5
Measured over: At week 16 (within each cohort)
Disease Control Rate (DCR) - Cohort 3
Measured over: at week 16
Overall Survival (OS) - Cohort 5
Measured over: Cohort 5: From the date of randomization through long term follow up at 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07280377 · record last updated 2026-05-19 · checked 2026-11-09 15:47 UTC